*3.5. The BCG.HTI2auxo.int* + *ChAdOx1.HTI Prime-Boost Regimen Is Well Tolerated*

Five adult mice per group were either left unimmunized or received 10<sup>6</sup> colony-forming units (cfu) of BCG wt or a total of 105 cfu of BCG.HTI2auxo.int intradermally, and five weeks later were boosted with 10<sup>9</sup> vp of ChAdOx1.HTI and their body mass was monitored regularly over time (Figure 6). The body mass curve corresponded to those of the provider (Envigo, Huntington, UK), and there were no statistically significant differences observed between the vaccine recipients and controls at any time point tested (Figure 6). Mice were monitored weekly for signs of malaise. No vaccine-related deaths, no local adverse events, and no associated systemic reactions were observed.

**Figure 6.** Safety of the BCG.HTI2auxo.int and ChAdOx1.HTI prime-boost regimen in BALB/c mice. Mice in groups of five (female, seven weeks old) were immunized i.d. with 105 colony-forming units (CFU) of BCG.HTI2auxo.int or 10<sup>6</sup> CFU BCGwt and boosted with 10<sup>9</sup> VP of ChAdOx1.HTI. Body weights were recorded regularly, and the mean for each group of mice is shown as mean ± SD (n = 5). Data from naive mice are presented as mean ± 2 SD (n = 5) (dashed grey lines).
